RxDoctor Payments Data

Daniel Donovan, MD

Neurology · Cookeville, TNNPI 1629068994

Payments from drug & device makers

$21,220in general payments, 2019–2025

Across 1,135 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Heartflow, Inc.$2K
  • AbbVie$1K
  • Biogen$1K
  • Novartis$948
  • plus $12K from 54 others

What the payments were for

  • Speaking & faculty fees$340%
  • Travel & lodging$1,2976%
  • Food & beverage$19,08290%
  • Education$8064%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.86$1,966
Teva Pharmaceuticals USA, Inc.123$1,605
Heartflow, Inc.6$1,526
AbbVie(2 entities)109$1,451
Biogen69$1,172
Novartis59$948
EMD Serono, Inc.52$921
Jazz Pharmaceuticals Inc.29$835
Lundbeck LLC45$829
Supernus Pharmaceuticals, Inc.36$569
Sumitomo Pharma America, Inc.36$553
Sanofi26$518
Pfizer32$518
Otsuka America Pharmaceutical, Inc.31$457
Eisai Inc.29$454
Sunovion Pharmaceuticals Inc.40$428
AstraZeneca(2 entities)21$424
Lilly USA, LLC26$422
SK Life Science, Inc.26$385
Corium, LLC15$326
Genentech USA, Inc.14$317
Bristol Myers Squibb15$293
Livanova USA, Inc.2$272
Neurocrine Biosciences, Inc.13$265
Johnson & Johnson17$261
Amneal Pharmaceuticals LLC12$253
Avanir Pharmaceuticals, Inc.15$252
Amgen13$236
Avadel CNS Pharmaceuticals, LLC9$216
Vanda Pharmaceuticals Inc.11$206
Acadia Pharmaceuticals Inc9$191
Biohaven Pharmaceutical Holding Company Ltd.8$164
MDD US Operations, LLC5$142
Biohaven Pharmaceuticals, Inc.9$140
Upsher-smith Laboratories LLC9$133
Neurelis, Inc.8$127
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$113
Grifols USA, LLC5$104
Harmony Biosciences LLC1$95
Ironshore Pharmaceuticals Inc.5$94
Inspire Medical Systems, Inc.2$80
Bausch Health US, LLC5$79
Impel Pharmaceuticals Inc.4$76
Argenx US, Inc.3$69
Tris Pharma Inc4$64
Merck3$51
Cycle Pharmaceuticals Inc3$48
Promius Pharma LLC3$43
Kyowa Kirin, Inc.2$43
Averitas Pharma Inc.1$41
Ipsen Biopharmaceuticals, Inc2$40
Banner Life Sciences, LLC2$37
Shire North American Group Inc2$37
Acorda Therapeutics, Inc2$34
Collegium Pharmaceutical, Inc.2$32
E.r. Squibb & Sons, L.L.C.2$30
Impel Pharmaceuticals LLC1$25
Merz Pharmaceuticals, LLC1$25
Axsome Therapeutics, Inc.1$23
Sanofi-aventis U.S. LLC1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,220 in reported general payments places this provider in the 70th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$212,786
Medicare patients
558
Services billed
4,529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EvrysdiRisdiplam15$393,979
Sodium Oxybate20$365,057
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5041$319,701
VumerityDiroximel Fumarate35$294,741
AustedoDeutetrabenazine13$191,055
Kesimpta PenOfatumumab14$140,418
NuplazidPimavanserin Tartrate25$114,998
AubagioTeriflunomide12$109,906
CopaxoneGlatiramer Acetate14$81,648
NuedextaDextromethorphan Hbr/Quinidine42$67,311
VraylarCariprazine Hcl43$61,979
Dimethyl Fumarate11$49,100
Teriflunomide13$48,432
Dalfampridine ErDalfampridine73$47,005
Nurtec OdtRimegepant Sulfate22$31,495

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech USA, Inc.Evrysdi$317$393,97915 claims
BiogenVumerity$1,172$294,74135 claims
Teva Pharmaceuticals USA, Inc.Austedo, Copaxone$1,605$272,70327 claims
Acadia Pharmaceuticals IncNuplazid$191$114,99825 claims
SanofiAubagio$518$109,90612 claims
AbbVieVraylar, Botox, Qulipta$1,451$101,48369 claims
Avanir Pharmaceuticals, Inc.Nuedexta$252$67,31142 claims
PfizerNurtec Odt$518$31,49522 claims
UCB, Inc.Briviact$1,966$21,46326 claims
Amneal Pharmaceuticals LLCRytary$253$19,49015 claims
Sunovion Pharmaceuticals Inc.Aptiom$428$19,23817 claims
Eisai Inc.Fycompa$454$17,46115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 361 neurology providers in Tennessee.

Other neurology in Cookeville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →